Drugs / BB-MPI-03
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02240537 | Jan 2015 → Dec 2016 | acute myeloid leukemia, myelodysplastic syndrome, smoldering plasma cell myeloma | Benovus Bio, Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BB-MPI-03 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02240537 ↗ |
| Route | Other | “BB-MPI-03 is emulsified with Montanide and administered intradermally (ID) within 1-2 cm of the 2 sargramostim injection sites 1-3 minutes after sargramostim administration.” NCT02240537 ↗ |